TNX-201

Tonix Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	TNX-201
Also known as	(R)-isometheptene mucate
Sponsor	Tonix Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache (PHASE2)
Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TNX-201 CI brief — competitive landscape report
TNX-201 updates RSS · CI watch RSS
Tonix Pharmaceuticals, Inc. portfolio CI